Recently, the Jiangsu Science and Technology Conference and the Provincial Science and Technology Awards Ceremony was held in Nanjing. The "Research and Development and Industrialization of Aumolertinib Mesilate, the Third-generation EGFR Lung Cancer Targeted Drug" project led by Hansoh Pharma won first prize among the Jiangsu Science and Technology Awards for 2023, making it the only pharmaceutical company to receive a top prize in this year's selection.
Aumolertinib Mesylate tablets (trade name: Ameile) are the first original third-generation EGFR-TKI developed by Hansoh Pharmaceutical in China. They have been approved in China for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed on prior EGFR-TKI therapy and are T790M mutation positive. They are also used for first-line treatment of adult patients with locally advanced or metastatic NSCLC who suffer from EGFR exon 19 deletion or exon 21 (L858R) substitution mutation-positive disease. This fills the medication gap in the domestic lung cancer sub-field. Both indications are now included in the national medical insurance catalog, significantly improving the accessibility and affordability of medication for patients.
In response to the challenges of drug resistance and brain metastasis in lung cancer treatment, Hansoh Pharma's R&D team creatively designed a novel drug molecule, Aumolertinib, which perfectly binds to the target protein EGFR. Aumolertinib irreversibly and highly selectively inhibits EGFR sensitive mutations and the T790M resistant mutation. By introducing a special lipophilic structure, it also offers significant clinical advantages to patients with brain metastasis. To date, Aumolertinib has received more than 40 authorized domestic and international invention patents, and the compound patent has won the "China Patent Gold Award" at the 24th session.
The Jiangsu Science and Technology Award, established by the Jiangsu Provincial People's Government, is the highest honor for innovation achievements within the province. Winning first prize is significant evidence of the company's technological innovation and R&D capabilities. Hansoh Pharma will continue to substantially boost its R&D investment and increasingly expedite the market launch of innovative drugs and treatment solutions to bring benefits to patients not only in China but also worldwide.
Statements
Hansoh Pharma does not recommend the use of any unapproved drugs or indications. Medical info in this release is for informational and news reporting only, and is not for advertising purposes. Don't use it for health care or diagnosis.
Forward-Looking Statements
This press release is intended to provide information about Hansoh Pharmaceutical Group Co., Ltd. and its affiliates, including their subsidiaries (collectively referred to as the "Hansoh Pharma"). It does not constitute a disclosure of information about the Hansoh Pharma or any investment recommendations.
The information contained in this release may include forward-looking statements related to the Hansoh Pharma's business and product prospects, as well as its plans, beliefs, expectations, and strategies. These statements are predictions based on speculative assumptions and are not guarantees of future performance. They are subject to risks and uncertainties, such as scientific, commercial, political, economic, financial, legal factors as well as competitive environment and social conditions, many of which are beyond the Hansoh Pharma's control and difficult to predict, thus actual results may differ significantly from what is stated here, and past securities price trends should not be used as a guide for future market conditions. As such, investors should exercise caution when using this information to make investment decisions. Phrases such as "commit," "expect," "believe," "predict," "anticipate," "forecast," "intent," “project,” “may,” “will,” “should,” “plan,” “could,” “continue,” “target,” “contemplate,” “estimate,” “guidance,” “possible,” “potential,” “pursue,” “likely,” and words and terms of similar terms substance used in connection with any discussion of future plans, actions or events indicate forward-looking statements.
The Hansoh Pharma does not commit to or guarantee the accuracy, timeliness, or completeness of forward-looking information and assumes no obligation to update or revise these forward-looking statements. Neither the Hansoh Pharma nor any of its directors, employees, or agents will be responsible for any forward-looking statements that prove to be inaccurate or unachievable and any losses or damages incurred by users due to reliance on the information provided herein, including but not limited to direct, incidental, indirect, or punitive damages.
All information in this press release is current as of the date of release. The Hansoh Pharma assumes no responsibility to update or revise this information in light of new developments, future events, or other circumstances, except as required by law. Additionally, the Hansoh Pharma reserve the right to make changes, corrections, or discontinuations to all or part of the content of this press release at any time without notice. For information specifically related to the listed company, investors are encouraged to refer to the announcements and financial reports of Hansoh Pharma (03692.HK).
